MA34760B1 - Composés et leurs utilisation - Google Patents

Composés et leurs utilisation

Info

Publication number
MA34760B1
MA34760B1 MA36039A MA36039A MA34760B1 MA 34760 B1 MA34760 B1 MA 34760B1 MA 36039 A MA36039 A MA 36039A MA 36039 A MA36039 A MA 36039A MA 34760 B1 MA34760 B1 MA 34760B1
Authority
MA
Morocco
Prior art keywords
compounds
restore
formula
lactamase
lactamase inhibitors
Prior art date
Application number
MA36039A
Other languages
English (en)
Inventor
Palanisamy Senthilkumar Udayampalayam
Maneesh Paul-Satyaseela
Shridhar Narayanan
Gopalan Balasubramanian
Aravind Appu
Senthilnathan Manickam
Hariharan Periasamy
Original Assignee
Allecra Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45757037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34760(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Gmbh filed Critical Allecra Therapeutics Gmbh
Publication of MA34760B1 publication Critical patent/MA34760B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/883—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a substituted hydrocarbon radical attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés et leur utilisation dans le traitement d'infections. Les composés de formule (I), leurs dérivés, analogues, formes tautomères, stéréo-isomères, polymorphes, solvates, sels pharmaceutiquement acceptables et les compositions pharmaceutiques décrits dans la présente invention sont également utiles comme inhibiteurs de la ²-lactamase, qui restaurent ou renforcent le spectre antibiotique d'un agent antibiotique approprié. Les composés de formule (I) font office d'inhibiteurs de ²-lactamases. Ces composés restaurent/potentialisent l'activité des antibiotiques à base de ²-lactamase à l'encontre de carbapénémases. Ces composés s'utilisent dans des méthodes diagnostiques pour détecter la présence de ²-lactamases.
MA36039A 2010-11-25 2013-06-24 Composés et leurs utilisation MA34760B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3555CH2010 2010-11-25
IN3096CH2011 2011-09-09
PCT/IN2011/000813 WO2012070071A1 (fr) 2010-11-25 2011-11-25 Composés et leur utilisation

Publications (1)

Publication Number Publication Date
MA34760B1 true MA34760B1 (fr) 2013-12-03

Family

ID=45757037

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36039A MA34760B1 (fr) 2010-11-25 2013-06-24 Composés et leurs utilisation

Country Status (30)

Country Link
US (1) US10201532B2 (fr)
EP (1) EP2642992B1 (fr)
JP (1) JP5961177B2 (fr)
KR (1) KR101933084B1 (fr)
CN (2) CN103347515B (fr)
AP (1) AP2013006947A0 (fr)
AU (1) AU2011333305B2 (fr)
BR (1) BR112013012735B1 (fr)
CA (1) CA2818100C (fr)
CL (1) CL2013001482A1 (fr)
CO (1) CO6781486A2 (fr)
CR (1) CR20130306A (fr)
DK (1) DK2642992T3 (fr)
EA (1) EA030662B1 (fr)
EC (1) ECSP13012716A (fr)
ES (1) ES2859639T3 (fr)
FR (1) FR24C1035I2 (fr)
HU (1) HUE053623T2 (fr)
IL (1) IL226538A (fr)
MA (1) MA34760B1 (fr)
MX (2) MX375266B (fr)
MY (1) MY170435A (fr)
NZ (1) NZ610247A (fr)
PE (1) PE20140716A1 (fr)
PH (1) PH12013501042A1 (fr)
SG (1) SG190877A1 (fr)
SV (1) SV2013004451A (fr)
UA (1) UA115966C2 (fr)
WO (1) WO2012070071A1 (fr)
ZA (1) ZA201303773B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2993900B1 (fr) * 2012-07-27 2016-03-25 Biomerieux Sa Procede de detection de bacteries productrices de carbapenemases de type oxa-48
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
US20140128364A1 (en) * 2012-11-05 2014-05-08 Rempex Pharmaceuticals Therapeutic uses of tigemonam and carumonam
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
JP2016010399A (ja) * 2014-06-03 2016-01-21 日水製薬株式会社 カルバペネマーゼ産生耐性菌検出用組成物
FR3024465B1 (fr) * 2014-07-30 2018-03-23 Biomerieux Caracterisation de micro-organismes par maldi-tof
EP3372587A1 (fr) * 2017-03-09 2018-09-12 Centre National de la Recherche Scientifique (CNRS) 3-imidazolines comme inhibiteurs de carbapenemases
SI25892A (sl) * 2019-09-05 2021-03-31 Gorenje Gospodinjski Aparati, D.O.O. Pralni stroj, ki se polni s sprednje strani, z električnim svetlobnim telesom
JP7630179B2 (ja) * 2019-09-11 2025-02-17 テンノア・セラピューティクス・（スージョウ）・リミテッド 細菌感染症を治療するためのペナム誘導体
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59118790A (ja) * 1982-12-24 1984-07-09 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
JPS60215688A (ja) * 1984-04-09 1985-10-29 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
JP2599595B2 (ja) * 1987-06-26 1997-04-09 大鵬薬品工業株式会社 ２β−置換メチルペニシラン酸誘導体、その塩及びエステル
US4891369A (en) 1986-12-03 1990-01-02 Taiho Pharmaceutical Company, Limited 2β-Substituted-methylpenicillanic acid derivatives, and salts and esters thereof
JP2648750B2 (ja) * 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
PL1468697T3 (pl) 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
JP2008516967A (ja) 2004-10-14 2008-05-22 ワイス 乳酸ナトリウム希釈液中にピペラシリン、タゾバクタムおよびアミノカルボン酸を含む組成物
WO2008010048A2 (fr) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Dérivés innovants 2-substitués du méthyl pénam
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments

Also Published As

Publication number Publication date
CA2818100A1 (fr) 2012-05-31
CL2013001482A1 (es) 2014-04-04
UA115966C2 (uk) 2018-01-25
KR101933084B1 (ko) 2018-12-28
US20140057888A1 (en) 2014-02-27
WO2012070071A1 (fr) 2012-05-31
BR112013012735A2 (pt) 2017-11-07
SG190877A1 (en) 2013-07-31
CN103347515B (zh) 2017-06-06
ZA201303773B (en) 2014-11-26
US10201532B2 (en) 2019-02-12
SV2013004451A (es) 2017-12-01
CN103347515A (zh) 2013-10-09
EA201300617A1 (ru) 2014-03-31
WO2012070071A9 (fr) 2012-08-16
AU2011333305A1 (en) 2013-07-11
JP5961177B2 (ja) 2016-08-02
MX353447B (es) 2018-01-11
HUE053623T2 (hu) 2021-07-28
ES2859639T3 (es) 2021-10-04
KR20140052927A (ko) 2014-05-07
FR24C1035I1 (fr) 2024-12-06
BR112013012735B1 (pt) 2021-11-23
EA030662B1 (ru) 2018-09-28
MX375266B (es) 2025-03-06
MY170435A (en) 2019-07-31
NZ610247A (en) 2014-09-26
BR112013012735A8 (pt) 2021-10-26
IL226538A (en) 2017-07-31
MX2013005907A (es) 2013-12-06
EP2642992B1 (fr) 2020-11-25
PH12013501042A1 (en) 2021-06-02
AP2013006947A0 (en) 2013-06-30
CN107260729B (zh) 2020-03-31
AU2011333305B2 (en) 2017-06-22
EP2642992A1 (fr) 2013-10-02
JP2014504279A (ja) 2014-02-20
CA2818100C (fr) 2019-07-09
FR24C1035I2 (fr) 2025-05-30
CN107260729A (zh) 2017-10-20
CO6781486A2 (es) 2013-10-31
DK2642992T3 (da) 2021-03-01
PE20140716A1 (es) 2014-07-12
CR20130306A (es) 2013-09-18
ECSP13012716A (es) 2013-08-30

Similar Documents

Publication Publication Date Title
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
MA38138A1 (fr) Dérivés inédits de quinolone
MA31419B1 (fr) Derives de pyridine
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA29926B1 (fr) Derives de pyrazine
TN2011000316A1 (fr) Derives de sulfonamides
NO20070155L (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
TNSN07022A1 (fr) Derives de pyridine
EA201300617A1 (ru) β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
MA30231B1 (fr) Derives de benzamides et d'heteroarenes
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA37405A1 (fr) Composés hétérocyclyle
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MX2010007375A (es) Nuevos derivados de lupano.
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER